Real-World adherence and quality of life Among HER2-positive breast cancer patients receiving subcutaneous trastuzumab in Ghana: A pilot study
{{output}}
BackgroundAdherence to trastuzumab is essential for achieving optimal outcomes in HER2-positive breast cancer; however, real-world data on adherence to subcutaneous formulations in low- and middle-income countries remain limited. This study evaluated adherence... ...
